Factor XII Dependent Coagulation, Thrombin And Platelet Glycoprotein 1ba In Arterial Thrombosis And Bleeding Disorders
Funder
National Health and Medical Research Council
Funding Amount
$104,664.00
Summary
Clot formation is the key event underlying heart attacks and strokes. There is new data that Factor XII (FXII) can play an important role in clot formation-thrombosis. We aim to examine the role FXII plays in clot formation, in particular the role of FXII in thrombin generation, which is the central event of clot formation, and its interaction with platelet glycoprotein 1ba (another important molecule in thrombosis). New insights into clotting and new therapies can result from our research.
Synovial Macrophages And T-cells Are Therapeutic Targets In Osteoarthritis
Funder
National Health and Medical Research Council
Funding Amount
$658,761.00
Summary
Osteoarthritis (OA) is the most widespread musculoskeletal disease in Australia and there are currently no therapies that halt disease progression. Specific inflammatory events play a pivotal role in initiating and driving OA progression. In this study we will define the specific inflammatory cells involved in OA, how and why they change with time, and which can be targeted to stop disease onset and development. This will provide the platform for initiating human clinical trials.
DIREKT: Disarming The Intravascular Innate Immune Response To Improve Modalities For Chronic Kidney Disease Treatment
Funder
National Health and Medical Research Council
Funding Amount
$362,830.00
Summary
Dialysis is the mainstay treatment for patients with end-stage kidney disease while they await transplantation. However, the dialysis process causes inflammation in patients, affecting their health and longevity. This project aims to develop new bioreagents that can be applied to dialysis devices to reduce inflammation and thus improve patient outcomes. These bioreagents will also be used to modify donor kidneys so that they are protected from inflammation associated with transplantation.
Signalling Pathways In Antibody-Mediated Renal Injury
Funder
National Health and Medical Research Council
Funding Amount
$113,296.00
Summary
Many types of kidney disease are induced by antibody binding to the kidney which initiates a damaging response by cells of the immune system. Current therapies for such diseases rely upon toxic immunosuppressive drugs. This project will examine one specific mechanism by which immune cells are activated by antibody to cause injury in human and experimental renal injury. These studies will determine whether this specific mechanism is a suitable target for developing new therapeutic drugs.
Understanding The Mechanism And Significance Of CXCL16-mediated Protection Of Tumour Cells From CTL-induced Apoptosis.
Funder
National Health and Medical Research Council
Funding Amount
$524,520.00
Summary
This research will begin to determine the significance of changes in the amount of a recently-discovered protein on the surface of tumour cells. We have shown that an increase in expression of this protein protects tumour cells from destruction by our immune system's killer T cells. The outcome of this research could lead to a better understanding of how the immune system recognises and kills tumour cells, and ultimately, alternate vaccine strategies for tumours.
Mechanisms Of Novel TLR9 Mediated Intraocular Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$442,244.00
Summary
Corneal opacities and scarring due to microbial and parasitic infections are a major cause of blindness globally. Novel studies in our lab have shown that topical application of bacterial/viral DNA alone to the cornea can cause previously unrecognised inflammation in the retina. Understanding the mechanisms of this retinal inflammation and how to block it may help in the design of novel treatments for a number of blinding conditions.